about
A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumoursCardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting.Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.Cardiac slices as a predictive tool for arrhythmogenic potential of drugs and chemicals.Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review.Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.Identification of drug targets related to the induction of ventricular tachyarrhythmia through a systems chemical biology approach.The clinical significance of QT prolongation associated with tamoxifen: A review of the literature.Risk factors for QTc-prolongation: systematic review of the evidence.Development of Safe Drugs: The hERG Challenge.Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study.Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance.QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature.Prevalence of QTc interval changes in acute psychiatric care: a cross-sectional study.Gastroparesis: pharmacotherapy and cardiac risk.Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
P2860
Q33159659-8AA8B3B4-79D4-4289-A84B-CED51C004EFDQ35566681-A457E7D3-26ED-4985-A075-F359463D740BQ36970774-AB0F02B9-E830-442F-BF32-537434C89599Q37808482-2C7F79B8-1128-4F06-A7B7-C8709FD8580EQ37844011-1CEB62B9-42A5-488E-91A1-500E40226A61Q37993589-D6C26719-FC0D-4D8A-B21D-9B877B4ECD01Q38465804-E54FE74A-BD3B-45CD-A909-788DE34E0196Q38669660-1935A91A-15F5-4CA2-BF72-54BD0F5BAE8EQ39052301-F999FC2A-0FD0-42EB-B743-C232E207D318Q39280559-3ADE00F4-F48C-4979-B395-90180CE95C67Q39816066-028FB1C0-81D2-4960-93DD-1186FF121641Q41203569-E9071122-7071-427B-96E6-D89410CA62A8Q47130381-EF188917-BC35-45B8-A1F7-AE4859C7E31EQ50715382-8920BCF1-436D-448D-9C61-D0D83B4CDDB3Q52777223-27354BA0-16B8-49B9-82CB-4269123482FEQ54478532-6CF89A42-7CBE-4D62-82E8-E7D20A6EA48A
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Mechanisms of drug induced QT interval prolongation.
@ast
Mechanisms of drug induced QT interval prolongation.
@en
type
label
Mechanisms of drug induced QT interval prolongation.
@ast
Mechanisms of drug induced QT interval prolongation.
@en
prefLabel
Mechanisms of drug induced QT interval prolongation.
@ast
Mechanisms of drug induced QT interval prolongation.
@en
P1433
P1476
Mechanisms of drug induced QT interval prolongation
@en
P2093
Guillermo Di Girolamo
Marcelo Luis Ponte
P356
10.2174/157488610789869247
P577
2010-01-01T00:00:00Z